Papers
3
Total Citations
132
H-Index
2
About
James Howard is a leading surgical oncologist whose research focuses on the optimal treatment of oropharyngeal squamous cell carcinoma (OPSCC), particularly in the context of the rising incidence of human papillomavirus (HPV)-associated disease. His major contributions center on comparing the efficacy of minimally invasive surgical techniques—such as transoral robotic surgery (TORS) and transoral laser microsurgery—against primary radiotherapy or chemoradiotherapy for early-stage and small-volume tumors. Howard’s work has been pivotal in shaping de-intensification strategies for HPV-positive OPSCC, a younger and often healthier patient population with significantly improved survival rates. His 2016 study, with 82 citations, provides critical evidence on the comparative outcomes of surgery versus radiation for small-volume primary disease, while his 2018 investigation into de-intensified adjuvant therapy post-surgery (48 citations) advances the goal of reducing treatment-related toxicity without compromising oncologic control. By systematically evaluating these approaches, Howard has helped define more personalized, less morbid treatment pathways. His research continues to influence clinical guidelines and offers a valuable framework for balancing cure with quality of life in head and neck cancer care.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3